J J Ifthikharuddin
Affiliation: University of Rochester
- CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximabJ J Ifthikharuddin
Department of Hematology Oncology, University of Rochester, Strong Memorial Hospital, Rochester, New York 14642, USA
Am J Hematol 65:171-3. 2000..We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment...
- Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipientsJane L Liesveld
Blood and Marrow Transplant Program, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
Biol Blood Marrow Transplant 8:662-5. 2002..This study demonstrates the feasibility and significant cost savings of using oral VAL for HSV prophylaxis...
- Impact of mobilized blood progenitor cell quality determined by the CFU-GM/CD34+ ratio on rapid engraftment after blood stem cell transplantationS Q Fu
Blood and Marrow Stem Cell Transplant Program, Department of Internal Medicine and The James P Wilmot Cancer Center, University of Rochester, New York 14642, USA
Blood Cells Mol Dis 28:315-21. 2002..The CFU-GM/CD34+ ratio is an apparent predictor of earlier platelet engraftment, suggesting that the ratio reflects the engraftment potential of mobilized donor progenitor cells...
- Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary reportG L Phillips
The James P Wilmot Cancer Center, BMT Program, Rochester, NY 14642, USA
Semin Oncol 31:59-61. 2004..Patient entry at the starting dose (ie, HD-MEL 140 mg/m2) has been completed without the development of severe regimen-related toxicities. This trial is ongoing...